AstraZeneca Sues KV Pharma Over ANDA For Toprol-XL Generic

Law360, New York (September 19, 2004, 12:00 AM EDT) -- U.K-Swedish drug maker AstraZeneca has sued generic maker KV Pharmaceutical Company for patent infringement over its plans to launch a 50 mg generic version of hypertension drug Toprol-XL.

AstraZeneca said it sued KV Pharma in the U.S. District Court for the District of Delaware as a result of a Paragraph IV Certification letter concerning KV Pharma’s intent to manufacture and sell Toprol-XL (metoprolol succinate) in the 50 mg dose form in the U.S.

Generics drug applicants must include with their abbreviated new drug applications (ANDAs) a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.